1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jiangsu Jibeier Pharmaceutical Co. Ltd. Class A

Jiangsu Jibeier Pharmaceutical Co. Ltd. Class A

SSSE:688566
26.60
CNY
+0.10
(+0.38%)
1.31EPS
19.40P/E
5.15BMarket Cap
Oct 30Next Earn
Jiangsu Jibeier Pharmaceutical Co. Ltd. Class A
SSE:688566
(Shanghai Stock Exchange)

Recent

price

26.60

P/E

ratio

19.40

div

yld

0.98%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.18
3.21
3.46
3.89
3.36
2.71
3.51
4.6
4.62
4.84
5.02
Revenue per Share
0.55
0.55
0.69
0.81
0.77
0.61
0.83
1.17
1.13
1.31
1.32
Basic EPS, GAAP
-0.05
0.66
0.64
0.61
0.56
0.35
-0.76
-1.06
0.21
0.67
- -
Free Cash Flow per Basic Share
0.03
0.04
1.21
0.08
0.27
0.48
0.48
0.24
0.53
0.52
0.26
Dividend per Share
2.54
3.1
2.5
3.31
8.4
8.57
9.03
10.07
11.28
12.18
12.51
Book Value per Share
2.16
2.72
2.03
2.85
8.06
8.24
8.71
9.77
10.83
11.43
11.73
Tangible Book Value per Share
140
141
140
139
168
188
186
187
194
200
200
Basic Weighted Avg Shares
444
452
485
543
566
510
655
861
897
966
1,004
Sales/Revenue/Turnover
18.95
20.58
22.99
24.03
23.72
21.65
24.41
28.86
32.91
25.74
25.4
Operating Margin (%)
12
13
12
13
13
13
13
11
11
18
- -
Depreciation Expense
77
78
97
113
130
115
155
219
219
262
264
Net Income, GAAP
14.53
16.04
14.42
13.1
12.57
13.74
11.61
11.6
13.57
13.33
14.1
Effective Tax Rate (%)
17.31
17.14
19.92
20.81
22.92
22.54
23.62
25.45
24.46
27.08
26.26
Profit Margin (%)
199
277
212
300
1,426
1,282
1,075
921
1,119
1,078
1,091
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
- -
LT Debt
363
441
358
470
1,576
1,608
1,694
1,910
2,254
2,450
2,533
Total Equity
- -
18.78
24.37
27.32
12.82
7.21
9.42
12.18
10.49
9.25
9
Return on Invested Capital (%)
- -
18.89
23.99
27.21
12.53
7.25
9.41
12.15
10.48
11.07
10.93
Return on Capital (%)
- -
19.6
24.61
27.72
12.76
7.25
9.4
12.19
10.56
11.18
10.96
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
17
2
12
LT Borrowings
2
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
199
199
201
Market Capitalization
5,953
5,855
5,146

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,255
1,256
1,250
Cash, Cash Equivalents & STI
818
770
869
Accounts Receivable, Net
224
173
216
Inventories
34
37
36
Total Current Liabilities
177
134
159
Payables & Accruals
- -
- -
- -
ST Debt
17
2
12
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.36%
8.69%
Free Cash Flow
- -
-38.92%
228.01%
Net Income, GAAP
- -
16.85%
19.28%
Sales/Revenue/Turnover
- -
12.38%
7.76%
Total Cash Common Dividend
- -
- -
0.73%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
194
239
210
253
897
2025
202
253
- -
262
966
2026
226
263
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.28
0.35
0.26
0.22
1.13
2025
0.25
0.5
- -
0.32
1.31
2026
0.21
0.28
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.26
0.53
2025
- -
- -
- -
- -
0.52
2026
- -
0.26
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SS) engages in the research, development, production, and sale of chemical pharmaceutical preparations, proprietary Chinese medicine preparations, and bulk medicines in China. The company offers tablets such as Leucogen tablets for improving white blood cells, Nitrendipine and Atenolol tablets for anti-hypertension, Aceclofenac Enteric-coated tablets for joint diseases, Asarone tablets, and Ricojun tablets; hard capsules including Yupingfeng capsules for enhancing immunity and Yiganling capsules for protecting liver function; eye drops such as Gatifloxacin eye drops and Lomefloxacin hydrochloride eye drops for anti-eye infection; and other forms like gels, creams, and agents for treating bronchitis, antipyretic and analgesic needs, respiratory conditions, cardiovascular drugs, blood system drugs, immune system drugs, and ophthalmic drugs. Founded in 2001 and headquartered in Zhenjiang High-tech Industrial Development Zone, Jiangsu Province, China, it operates primarily in the domestic market with approximately 1,327 employees and listed on the Shanghai Stock Exchange STAR Market in 2020. Recent developments include receipt in July 2025 of approval from the National Medical Products Administration for clinical trials of its new anti-tumor drug JJH201601 liposome injection, both as monotherapy for advanced solid tumors including pancreatic, biliary tract, and hepatocellular cancers, and in combination with Cetuximab (β) and/or Tremelimumab for advanced head and neck squamous cell carcinoma, with Phase I dose escalation completed and expansion ongoing; positive Phase III results for new antidepressant JJH201501, with marketing application materials in preparation; and ongoing Phase III enrollment for JJH201501, advancing its pipeline in oncology and central nervous system disorders.